Full Text
PCN69 COST-EFFECTIVENESS OF FIRST-LINE COMBINATION TREATMENT WITH BEVACIZUMAB PLUS FOLFIRI VERSUS FOLFIRI IN PATIENTS WITH METASTATIC COLORECTAL CANCER- A UK PERSPECTIVE

Abstract

Authors

M Gyldmark R Aultman U Siebert E Sabate

Back to Volume 12, Issue 3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×